Status:
UNKNOWN
Myocarditis After SARS-CoV2-Vaccination
Lead Sponsor:
Theresien Hospital Mannheim
Collaborating Sponsors:
University Hospital Heidelberg, GER
GRN Hospital Weinheim, GER
Conditions:
Myocarditis and Cardiomyopathy
Eligibility:
All Genders
Brief Summary
Background The novel coronavirus disease 2019 (COVID-19) caused by an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic with more tha...
Eligibility Criteria
Inclusion
- SARS-CoV-2 Vaccine-associated Myocarditis (\< 30 days after vaccination) confirmed by cardiac MRI without evidence of alternative etiology (infectious, auto-immune myocarditis).
Exclusion
- missing individual consent
Key Trial Info
Start Date :
November 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05268458
Start Date
November 12 2021
End Date
June 1 2022
Last Update
March 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Theresienkrankenhaus
Mannheim, Baden-Wurttemberg, Germany, 65168